1454847-96-1

Basic information

• Product Name: (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol
• Synonyms: (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol;EOS-60623;Benzenemethanol, 5-fluoro-2-iodo-α-methyl-, (αS)-
• CAS NO: 1454847-96-1
• Molecular Formula: C8H8FIO
• Molecular Weight: 266.0513932
• Mol File: 1454847-96-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 275.7±30.0 °C(Predicted)
• Appearance: /
• Density: 1.812±0.06 g/cm3(Predicted)
• PKA: 13.80±0.20(Predicted)
• CAS DataBase Reference: (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol(1454847-96-1)
• EPA Substance Registry System: (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol(1454847-96-1)

Safety Data

• Hazardous Substances Data: 1454847-96-1(Hazardous Substances Data)

Usage

Description

(S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol is an organic compound that serves as a crucial intermediate in the synthesis of Lorlatinib, a medication used for the treatment of cancer. It is characterized by its unique molecular structure, which includes a fluorine atom and an iodine atom attached to a phenyl ring, with an ethan-1-ol group attached to the stereocenter.

Uses

Used in Pharmaceutical Industry:
(S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol is used as a key intermediate in the synthesis of Lorlatinib, an orally administered inhibitor of ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1). These enzymes are known to contribute to the development and progression of certain types of cancer. By inhibiting the activity of these enzymes, Lorlatinib can help slow down or stop the growth of cancer cells, making (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol an essential component in the development of this targeted cancer therapy.
Additionally, due to its unique chemical properties, (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol may have potential applications in other areas of the pharmaceutical industry, such as the development of new drugs or drug delivery systems. However, further research and development would be required to explore these possibilities.

Physical Form

Solid or liquid

Upstream product

• 1634-04-4 tert-butyl methyl ether 
• 914225-70-0 1-(5-fluoro-2-iodophenyl)ethan-1-one 
• 394-32-1 1-(5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 877264-44-3 5-fluoro-2-iodobenzaldehyde 
• 75-16-1 methylmagnesium bromide 
• 877264-43-2 (5-fluoro-2-iodophenyl)methanol 
• 52548-63-7 5-fluoro-2-iodobenzoic acid 
• 446-08-2 2-amino-5-fluorobenzoic acid 

Relevant articles and documents

Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-methylisobenzofuran-1(3H)-one, a Key Intermediate to Lorlatinib

Synthesis of (S)-5-fluoro-3-methylisobenzofuran-1(3H)-one (6), a key intermediate to lorlatinib, is described. A few synthetic methodologies, that is, boron reduction, enzymatic reduction, asymmetric hydrogenation, and asymmetric transfer hydrogenation, were evaluated for the chiral reduction of the substituted acetophenone intermediate (8). A manufacturing process, on the basis of the asymmetric transfer hydrogenation, was developed. This process was successfully scaled up to prepare 400 kg of 6.

Benzoxadiazepine tetradecene derivative and application thereof

The invention discloses a benzoxadiazepine tetradecene derivative and application thereof, belonging to the field of medicines. The benzoxadiazepine tetradecene derivative with a structure as shown ina general formula (I) has excellent anaplastic lymphoma enzyme (ALK) inhibition activity and excellent pharmacodynamic performance, and can obviously prolong the large metabolic half-life period of adrug; the derivative can be safely and effectively used for treating anaplastic lymphoma kinase positive (ALK+) metastatic (advanced) non-small cell lung cancer (NSCLC) and the like, thereby providing a new means for treating cancers, metabolic and immune diseases, cardiovascular diseases, neurological diseases and the like.

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners

Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clinical trials for the treatment of ALK positive or ROS1 positive NSCLC (i.e. specific subsets of NSCLC). One of the laboratory objectives for this molecule indicated that it would be desirable